Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics

针对新型阿片类药物使用障碍治疗的 Ghrelin 系统

基本信息

项目摘要

PROJECT SUMMARY Opioid overdose deaths and the rise in problematic opioid use patterns that indicate the development of opioid use disorder (OUD) have reached crisis levels in the United States. Behavioral interventions coupled with medication-assisted treatment (MAT), such as the partial opioid agonist buprenorphine, reduce repeated opioid overdoses and substantially improve the odds of successful recovery in OUD. While current MAT is a chief adjunct in the proper management of OUD patients, this crisis has crystalized the need to identify novel, non- opioid therapeutics for this chronic medical disorder. Neuroplasticity within the interconnected nodes of the meso-corticostriatal circuit contributes to the enhanced motivational attributes of abused drugs and drug- associated cues, key factors in sustained OUD and relapse. In this light, we identified ghrelin as an endogenous regulator of this therapeutically-relevant circuit. Ghrelin acts by binding to the growth hormone secretagogue receptor 1α (GHS1αR) to transduce several physiological and behavioral processes, including the reward- related effects of opioid agonists. We discovered that systemic administration of a GHS1αR antagonist/inverse agonist dose-dependently attenuated self-administration of the abused opioid analgesic oxycodone as well as oxycodone-seeking. During the UG3 phase, we will leverage this new knowledge and employ a suite of validated rodent OUD models to define the preclinical profile for PF5190457, a selective GHS1αR antagonist/inverse agonist developed by Pfizer which has advanced into clinical trials. We will assess PF5190457 to block oxycodone intake without abuse liability and to suppress oxycodone withdrawal and relapse-like behaviors in male and female rats. We will also determine the drug metabolism and pharmacokinetics (DMPK) interaction between oxycodone and PF5190457 and brain penetrability of PF5190457 in opioid-experienced rats. With achievement of the UG3 preclinical milestones, we will work with NIDA to partner with Pfizer for Phase 1 clinical studies in non-treatment seeking OUD participants through assessment of the safety and tolerability of PF5190457 following oral oxycodone administration relative to placebo, the DMPK profile of oral oxycodone in OUD participants following PF5190457 (vs. placebo) dosing, and the subjective response to oral oxycodone following PF5190457 (vs. placebo). The second goal of the UH3 phase is to develop the preclinical data to support the prospect that PF5190457 may serve as an adjuvant therapy to reduce the dose of buprenorphine required for MAT. The small molecule GHS1αR antagonist/inverse agonist PF5190457 is a novel target for an OUD medication and achievement of the UG3 milestones demonstrating its effectiveness in the comprehensive preclinical analyses will provide the foundation for the UH3 to characterize PF5190457 as a potential treatment for OUD. The outcomes of the UG3/UH3 will have a sustained, powerful impact in our field with the prospect to validate a novel medication for OUD.
项目摘要 阿片类药物过量死亡和表明阿片类药物发展的有问题的阿片类药物使用模式的增加 使用障碍(OUD)在美国已达到危机水平。行为干预加上 药物辅助治疗(MAT),如部分阿片类激动剂丁丙诺啡,减少重复阿片类 过量并大大提高了OUD成功恢复的几率。虽然目前的MAT是一个首席 在OUD患者的适当管理的辅助,这场危机已经结晶需要确定新的,非 阿片类药物治疗这种慢性疾病。神经可塑性内的互连节点的 中皮质纹状体回路有助于增强滥用药物和药物的动机属性, 相关线索,持续OUD和复发的关键因素。鉴于此,我们将生长激素释放肽鉴定为内源性 这个治疗相关回路的调节器。生长激素释放肽通过与生长激素促分泌素结合而起作用 受体1α(GHS 1 αR)参与多种生理和行为过程,包括奖赏- 阿片类激动剂的相关作用。我们发现全身给予GHS 1 αR拮抗剂/逆转录酶抑制剂, 激动剂剂量依赖性减弱滥用阿片类镇痛药羟考酮的自我给药,以及 寻求羟考酮在UG 3阶段,我们将利用这些新知识,并采用一套经过验证的 啮齿类动物OUD模型,以确定PF 5190457(一种选择性GHS 1 αR拮抗剂/反向剂)的临床前特征 辉瑞公司开发的激动剂,已进入临床试验阶段。我们将评估PF 5190457以阻止 羟考酮摄入无滥用倾向,并抑制羟考酮戒断和复发样行为 雄性和雌性大鼠。我们还将确定药物代谢和药代动力学(DMPK)的相互作用 羟考酮和PF 5190457之间的关系以及PF 5190457在阿片类药物经验大鼠中的脑渗透性。与 为了实现UG 3临床前里程碑,我们将与NIDA合作,与辉瑞合作进行1期临床试验, 在非寻求治疗的OUD受试者中进行的研究,通过评估 PF 5190457口服羟考酮给药后相对于安慰剂, PF 5190457(vs.安慰剂)给药后的OUD受试者以及对口服羟考酮的主观反应 PF 5190457(vs.安慰剂)后。UH 3阶段的第二个目标是开发临床前数据,以支持 PF 5190457可能作为一种辅助治疗,以减少所需丁丙诺啡剂量的前景 关于MAT小分子GHS 1 αR拮抗剂/反向激动剂PF 5190457是OUD的新靶点 药物和UG 3里程碑的实现,证明其在综合治疗中的有效性 临床前分析将为UH 3将PF 5190457表征为潜在治疗提供基础 对于OUD。UG 3/UH 3的成果将在我们的领域产生持续的、强大的影响,其前景是 验证一种治疗OUD的新药。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kathryn A. Cunningham其他文献

Proteomics analyses: Peroxisome proliferator-activated receptor gamma agonist for chronic cocaine administration in rodents
  • DOI:
    10.1016/j.drugalcdep.2015.07.590
  • 发表时间:
    2015-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Nilesh S. Tannu;Joy Schmitz;Scott D. Lane;C. Green;Kathryn A. Cunningham;Robert Suchting;Juan Herrera;P.A. Narayana
  • 通讯作者:
    P.A. Narayana
Changes in brain white matter integrity after Ppar-gamma agonist treatment for cocaine use disorder
  • DOI:
    10.1016/j.drugalcdep.2016.08.316
  • 发表时间:
    2017-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Scott D. Lane;Khader M. Hasan;Benson Mwangi;P.A. Narayana;Jessica Vincent;F. Gerard Moeller;Joel Steinberg;Kelly Dineley;Kathryn A. Cunningham;Joy Schmitz
  • 通讯作者:
    Joy Schmitz
Novel bivalent serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands demonstrate distinct activities <em>in vitro and in vivo</em>
  • DOI:
    10.1016/j.drugalcdep.2015.07.1164
  • 发表时间:
    2015-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rachel M. Hartley;Scott Gilbertson;Ying-Chu Chen;Noelle C. Anastasio;Robert G. Fox;Sonja J. Stutz;Cheryl Watson;Kathryn A. Cunningham
  • 通讯作者:
    Kathryn A. Cunningham
Effective connectivity of attentional bias in cocaine dependence
  • DOI:
    10.1016/j.drugalcdep.2016.08.405
  • 发表时间:
    2017-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    F. Gerard Moeller;Liangsuo Ma;Joel Steinberg;James Bjork;Scott D. Lane;P.A. Narayana;Thomas Kosten;Antoine Bechara;Joy Schmitz;Amanda E. Price;Kathryn A. Cunningham
  • 通讯作者:
    Kathryn A. Cunningham
The SoTL Scaffold: Supporting Evidence-Based Teaching Practice in Educational Development
SoTL 支架:支持教育发展中的循证教学实践
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Laura Cruz;Kathryn A. Cunningham;Brian Smentkowski;H. Steiner
  • 通讯作者:
    H. Steiner

Kathryn A. Cunningham的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kathryn A. Cunningham', 18)}}的其他基金

Novel Addiction Neurocircuits in Cocaine Taking
可卡因吸食中的新型成瘾神经回路
  • 批准号:
    10595681
  • 财政年份:
    2022
  • 资助金额:
    $ 223.03万
  • 项目类别:
Mechanisms of prenatal opioid exposure on brain and behavior
产前阿片类药物暴露对大脑和行为的机制
  • 批准号:
    10375927
  • 财政年份:
    2022
  • 资助金额:
    $ 223.03万
  • 项目类别:
Novel Addiction Neurocircuits in Cocaine Taking
可卡因吸食中的新型成瘾神经回路
  • 批准号:
    10375964
  • 财政年份:
    2022
  • 资助金额:
    $ 223.03万
  • 项目类别:
Mechanisms of prenatal opioid exposure on brain and behavior
产前阿片类药物暴露对大脑和行为的机制
  • 批准号:
    10657323
  • 财政年份:
    2022
  • 资助金额:
    $ 223.03万
  • 项目类别:
NOP Receptor Antagonist for OUD Pharmacotherapy
用于 OUD 药物治疗的 NOP 受体拮抗剂
  • 批准号:
    10085851
  • 财政年份:
    2020
  • 资助金额:
    $ 223.03万
  • 项目类别:
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
针对新型阿片类药物使用障碍治疗的 Ghrelin 系统
  • 批准号:
    10168769
  • 财政年份:
    2019
  • 资助金额:
    $ 223.03万
  • 项目类别:
Neural and Pharmacological Mechanisms of Abused Drugs
滥用药物的神经和药理学机制
  • 批准号:
    9404132
  • 财政年份:
    2016
  • 资助金额:
    $ 223.03万
  • 项目类别:
5-HT2 Receptor Allosterism in Cocaine Use Disorder
可卡因使用障碍中的 5-HT2 受体变构
  • 批准号:
    10445173
  • 财政年份:
    2015
  • 资助金额:
    $ 223.03万
  • 项目类别:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
5-HT2CR 变构调节剂作为可卡因使用障碍的新型药物治疗
  • 批准号:
    9271312
  • 财政年份:
    2015
  • 资助金额:
    $ 223.03万
  • 项目类别:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
5-HT2CR 变构调节剂作为可卡因使用障碍的新型药物治疗
  • 批准号:
    9480142
  • 财政年份:
    2015
  • 资助金额:
    $ 223.03万
  • 项目类别:

相似海外基金

Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335802
  • 财政年份:
    2024
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335801
  • 财政年份:
    2024
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
A Longitudinal Study of the Relationship between Participation in a Comprehensive Exercise Program and Academic Achievement
参加综合锻炼计划与学业成绩之间关系的纵向研究
  • 批准号:
    24K14615
  • 财政年份:
    2024
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: Characterizing Best Practices of Instructors who Have Narrowed Performance Gaps in Undergraduate Student Achievement in Introductory STEM Courses
合作研究:缩小本科生 STEM 入门课程成绩差距的讲师的最佳实践
  • 批准号:
    2420369
  • 财政年份:
    2024
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335800
  • 财政年份:
    2024
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
WTG: Diffusion of Research on Supporting Mathematics Achievement for Youth with Disabilities through Twitter Translational Visual Abstracts
WTG:通过 Twitter 翻译视觉摘要传播支持残疾青少年数学成就的研究
  • 批准号:
    2244734
  • 财政年份:
    2023
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
The Impact of Emotional Experiences of Pride on Long-Term Goal Achievement Behaviors in Elite Athletes
骄傲的情感体验对优秀运动员长期目标实现行为的影响
  • 批准号:
    23K16740
  • 财政年份:
    2023
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Meta-Analysis of the Instructional-Relational Model of Student Engagement and Math Achievement: A Moderation and Mediation Approach
学生参与度和数学成绩的教学关系模型的元分析:一种调节和中介方法
  • 批准号:
    2300738
  • 财政年份:
    2023
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Standard Grant
Improving maths achievement in children with speech, language, and communication needs through 'collaborative vocabulary teaching'
通过“协作词汇教学”提高有言语、语言和交流需求的儿童的数学成绩
  • 批准号:
    2890475
  • 财政年份:
    2023
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Studentship
HSI Institutional Transformation Project: Retention and Achievement for Introductory STEM English Learners (RAISE)
HSI 机构转型项目:STEM 英语入门学习者的保留和成就 (RAISE)
  • 批准号:
    2225178
  • 财政年份:
    2023
  • 资助金额:
    $ 223.03万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了